Sign in Subscribe

Archive

A collection of 715 issues

Latest

Patient-Provider Relationship Quality Linked to Screening Uptake

Skip to content The CRC Digest Patient-Provider Relationship Quality Linked to Screening Uptake A national study using HINTS data from 7,732 US adults aged 45-75 found that patient-provider relationship quality may influence colorectal cancer screening uptake. (Cureus) This content is informational only and does not constitute medical advice. Always

Systematic Review Examines CRC Screening Uptake in People Living With HIV

Skip to content The CRC Digest Systematic Review Examines CRC Screening Uptake in People Living With HIV A systematic review and meta-analysis synthesized evidence on colorectal cancer screening uptake and lesion detection rates in people living with HIV, including comparisons with HIV-negative controls. (HIV Medicine) This content is informational only

Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer A phase Ib study to assess the safety of neoadjuvant trifluridine/tipiracil combined with concurrent radiation in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer) This content

Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer

Skip to content The CRC Digest ◇ RESEARCH Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer Preclinical research shows that 5-fluorouracil treatment promotes mitochondrial biogenesis and increased mitochondrial function in surviving colorectal cancer cells, and that targeting mitochondrial metabolism—particularly Complex I inhibition—can sensitize CRC cells to chemotherapy. (Nature Metabolism)

Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer

Skip to content The CRC Digest ◆ TRIAL DATA Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer A phase 1/2 trial testing copanlisib (a PIK3CA inhibitor) combined with nivolumab in metastatic microsatellite stable CRC did not meet its primary endpoint, with 0 of 17 PIK3CA-wildtype

Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy

Skip to content The CRC Digest ◇ RESEARCH Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy A study examined the incidence and risk factors of non-neutropenic enterocolitis—a potentially serious side effect—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin chemotherapy. (Clinical Colorectal Cancer) This content is informational only and

CRC Research Update — July 24, 2026

Today's colorectal cancer research highlights

MSI-H/dMMR Prevalence Documented in Japanese CRC Registry

Skip to content The CRC Digest MSI-H/dMMR Prevalence Documented in Japanese CRC Registry A multicenter study of 1,464 Japanese patients with primary colorectal cancer enrolled from April 2024 to March 2025 investigated the frequency and features of MSI-H/dMMR tumors to support personalized treatment strategies. (Annals of Gastroenterological

Metastatic CRC Diagnosed Before Age 35 May Be a Distinct Subset

Skip to content The CRC Digest Metastatic CRC Diagnosed Before Age 35 May Be a Distinct Subset An Australasian registry study compared demographic and clinicopathologic characteristics of metastatic colorectal cancer patients diagnosed before age 35 with those diagnosed at 35–49 years and ≥50 years. (International Journal of Cancer) This

Circulating Tumor DNA Test Evaluated for Predicting Stage III Recurrence

Skip to content The CRC Digest ♥ LIVING WITH CRC Circulating Tumor DNA Test Evaluated for Predicting Stage III Recurrence The α-CORRECT study evaluated a blood test for circulating tumor DNA in patients with stage III colorectal cancer after surgery and chemotherapy to detect tiny traces of cancer that may signal